Irodalom:
1. Andre T, Tournigand C, Achille E, Tubiana-Mathieu N, Lledo G, Raoul Y, Carola E,Flesch M, Muron T,
Boutan-Laroze A, Guerin Meyer V, Boaziz C, Maigre M, Ganem G,Mousseau M, Mounedji-Boudiaf
L, de Gramont A.: Adjuvant treatment of colon cancer MOSAIC study’s main results. Bull Cancer. 2006
Feb 1;93 Suppl 1:S5-9.
2. Hershman D, Hall MJ, Wang X, Jacobson JS, McBride R, Grann VR, Neugut AI.: Timing of adjuvant
chemotherapy initiation after surgery for stage III colon cancer. Cancer. 2006 Dec 1;107 (11):2581-8.
3. Andre T, Sargent D, Tabernero J, O’Connell M, Buyse M, Sobrero A, Misset JL, Boni C, de Gramont A.:
Current issues in adjuvant treatment of stage II colon cancer. Ann Surg Oncol. 2006 Jun;13 (6):887-98.
Epub 2006 Apr 14.
4. Yoshimatsu K, Umehara A, Ishibashi K, Yokomizo H, Yoshida K, Fujimoto T, Watanabe K, Ogawa K.:
Indication and efficacy of adjuvant chemotherapy with oral fluoropyrimidines for dukes’ B colorectal
cancer. Anticancer Res. 2006 Jul-Aug;26 (4B):3089-93.
5. Gill S, Sargent D.: End points for adjuvant therapy trials: has the time come to accept disease-free survival
as a surrogate end point for overall survival? Oncologist. 2006 Jun;11 (6):624-9.
6. Dobie SA, Baldwin LM, Dominitz JA, Matthews B, Billingsley K, Barlow W.: Completion of therapy by
Medicare patients with stage III colon cancer. J Natl Cancer Inst. 2006 May 3;98 (9):610-9.
7. Lamberti C, Lundin S, Bogdanow M, Gorschluter M, Schmidt-Wolf IG, Sauerbruch T.: Adjuvant and
palliative chemotherapy of colorectal cancer in Germany outside controlled trials. Dtsch Med
Wochenschr. 2006 Mar 10;131 (10):485-90.
8. H. S. Hochster, L. L. Hart, R. K. Ramanathan, J. D. Hainsworth, E. E. Hedrick, B. H. Childs:
Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line
248 Gastro Update 2007
treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE-Study. Journal of
Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20
Supplement), 2006: 3510
9. A. Venook, D. Niedzwiecki, D. Hollis, S. Sutherland, R. Goldberg, S. Alberts, A. Benson, J. Wade, R. Schilsky,
R. Mayer: Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) \” cetuximab
for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB
80203 preliminary results.
Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June
20 Supplement), 2006: 3509
10. Lenz HJ, Van Cutsem E, Khambata-Ford S, Mayer RJ, Gold P, Stella P, Mirtsching B, Cohn AL, Pippas
AW, Azarnia N, Tsuchihashi Z, Mauro DJ, Rowinsky EK.: Multicenter phase II and translational study
of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
J Clin Oncol. 2006 Oct 20;24 (30):4914-21.
11. Souglakos J, Kalykaki A, Vamvakas L, Androulakis N, Kalbakis K, Agelaki S, Vardakis N, Tzardi M,
Kotsakis AP, Gioulbasanis J, Tsetis D, Sfakiotaki G, Chatzidaki D, Mavroudis D, Georgoulias V.: Phase
II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal
cancer who progressed after oxaliplatin-based chemotherapy. Ann Oncol. 2006 Nov 1;
12. C. Koehne, E. Bajetta, E. Lin, E. Van Cutsem, J. Hecht, J. Douillard, M. Moore, C. Germond, D. Laurent,
C. Jacques: Results of an interim analysis of a multinational randomized, double-blind, phase III study
in patients (pts) with previously treated metastatic colorectal cancer (mCRC) receiving FOLFOX4 and
PTK787/ZK 222584 (PTK/ZK) or placebo (CONFIRM 2).
Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June
20 Supplement), 2006: 3508
13. Vincenzi B, Santini D, Russo A, Silletta M, Gavasci M, Battistoni F, Di Cuonzo G, Rocci L, Gebbia N,
Tonini G.: Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment
in advanced colorectal cancer patients. Ann Oncol. 2006 May;17 (5):835-41. Epub 2006 Feb 28.
14. Hebbar M, Tournigand C, Lledo G, Mabro M, Andre T, Louvet C, Aparicio T, Flesch M, Varette C, de
Gramont A.: Phase II trial alternating FOLFOX-6 and FOLFIRI regimens in second-line therapy of
patients with metastatic colorectal cancer (FIREFOX study). Oncology Multidisciplinary Research
Group (GERCOR). Cancer Invest. 2006 Mar;24 (2):154-9.
15. Jeung HC, Rha SY, Cho BC, Yoo NC, Roh JK, Roh WJ, Chung HC, Ahn JB.: A phase II trial of S-1
monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens.
Br J Cancer. 2006 Dec 18;95 (12):1637-41. Epub 2006 Nov 14.
16. Feliu J, Salud A, Escudero P, Lopez-Gomez L, Bolanos M, Galan A, Vicent JM, Yubero A, Losa F, De
Castro J, de Mon MA, Casado E, Gonzalez-Baron M.: XELOX (capecitabine plus oxaliplatin) as first-line
treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br J Cancer. 2006
Apr 10;94 (7):969-75.
17. Scartozzi M, Falcone A, Pucci F, Braconi C, Pierantoni C, Cavanna L, Franciosi V, Berardi R, Beretta G,
Masi G, Allegrini G, Zaniboni A, Labianca R, Cascinu S.: Capecitabine and mitomycin C may be an
effective treatment option for third-line chemotherapy in advanced colorectal cancer. Tumori. 2006
Sep-Oct;92 (5):384-8.
18. Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, Mineur L, Carola E, Etienne PL,
Rivera F, Chirivella I, Perez-Staub N, Louvet C, Andre T, Tabah-Fisch I, de Gramont A.: OPTIMOX1:
a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced
colorectal cancer–a GERCOR study. J Clin Oncol. 2006 Jan 20;24 (3):394-400.
19. Andre T, Tournigand C, Mineur L, Fellague-Chebra R, Flesch M, Mabro M, Hebbar M, Postel Vinay S,
Bidard FC, Louvet C, de Gramont A.: Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy
(OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study. Ann Oncol. 2006 Oct 9;
20. Petrioli R, Paolelli L, Marsili S, Civitelli S, Francini E, Cioppa T, Roviello F, Nettuno R, Intrivici C,
Tanzini G, Lorenzi M, Francini G.: FOLFOX-4 Stop and Go and Capecitabine Maintenance
A vastagbél 249
Chemotherapy in the Treatment of Metastatic Colorectal Cancer. Oncology. 2006 Dec 15;70 (5):345-350
21. F. Maindrault-Goebel, G. Lledo, B. Chibaudel, L. Mineur, T. Andre, M. Bennamoun, M. Mabro, P. Artru,
C. Louvet, A. De Gramont: OPTIMOX2, a large randomized phase II study of maintenance therapy or
chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC).
A GERCOR study. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24,
No. 18S (June 20 Supplement), 2006: 3504
22. R. Labianca, I. Floriani, E. Cortesi, L. Isa, A. Zaniboni, M. Marangolo, L. Frontini, S. Barni, G. D.
Beretta, A. Sobrero: Alternating versus continuous „FOLFIRI” in advanced colorectal cancer (ACC): A
randomized „GISCAD” trial. Italian Group for the Study of Digestive Tract Can Journal of Clinical
Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement),
2006: 3505
23. Portier G, Elias D, Bouche O, Rougier P, Bosset JF, Saric J, Belghiti J, Piedbois P, Guimbaud R,
Nordlinger B, Bugat R, Lazorthes F, Bedenne L.: Multicenter randomized trial of adjuvant fluorouracil
and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD
ACHBTH AURC 9002 trial. J Clin Oncol. 2006 Nov 1;24 (31):4976-82.
24. Nelson R, Freels S.: Hepatic artery adjuvant chemotherapy for patients having resection or ablation of
colorectal cancer metastatic to the liver. Cochrane Database Syst Rev. 2006 Oct 18; (4):CD003770.
25. Sahajpal A, Vollmer CM Jr, Dixon E, Chan EK, Wei A, Cattral MS, Taylor BR, Grant DR, Greig PD,
Gallinger S.: Chemotherapy for colorectal cancer prior to liver resection for colorectal cancer hepatic
metastases does not adversely affect peri-operative outcomes. J Surg Oncol. 2006 Oct 25;95 (1):22-27
[Epub ahead of print]
26. Amersi FF, McElrath-Garza A, Ahmad A, Zogakis T, Allegra DP, Krasne R, Bilchik AJ.: Long-term survival
after radiofrequency ablation of complex unresectable liver tumors. Arch Surg. 2006 Jun;141 (6):581-7;
discussion 587-8.
27. Jakobs TF, Hoffmann RT, Trumm C, Reiser MF, Helmberger TK.: Radiofrequency ablation of colorectal
liver metastases: mid-term results in 68 patients. Anticancer Res. 2006 Jan-Feb;26 (1B):671-80.
28. Ruers TJ, Joosten JJ, Wiering B, Langenhoff BS, Dekker HM, Wobbes T, Oyen WJ,Krabbe PF, Punt CJ.:
Comparison Between Local Ablative Therapy and Chemotherapy for Non-Resectable Colorectal Liver
Metastases: A Prospective Study. Ann Surg Oncol. 2006 Dec 31;
29. Abitabile P, Hartl U, Lange J, Maurer CA.: Radiofrequency ablation permits an effective treatment for
colorectal liver metastasis. Eur J Surg Oncol. 2006 Dec 12;
30. Machi J, Oishi AJ, Sumida K, Sakamoto K, Furumoto NL, Oishi RH, Kylstra JW.: Long-term outcome
of radiofrequency ablation for unresectable liver metastases from colorectal cancer: evaluation of prognostic
factors and effectiveness in first- and second-line management. Cancer J. 2006 Jul-Aug;12 (4):318-26.
31. Pacella CM, Valle D, Bizzarri G, Pacella S, Brunetti M, Maritati R, Osborn J, Stasi R.: Percutaneous
laser ablation in patients with isolated unresectable liver metastases from colorectal cancer: Results of
a phase II study. Acta Oncol. 2006;45 (1):77-83.
32. Kemeny NE, Niedzwiecki D, Hollis DR, Lenz HJ, Warren RS, Naughton MJ, Weeks JC, Sigurdson ER,
Herndon JE 2nd, Zhang C, Mayer RJ.: Hepatic arterial infusion versus systemic therapy for hepatic
metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers
(CALGB 9481). J Clin Oncol. 2006 Mar 20;24 (9):1395-403. Epub 2006 Feb 27.
33. J. Cassidy, G. A. Bjarnason, T. Hickish, C. Topham, M. Provencio, G. Bodoky, L. Landherr, P. Koralewski,
G. Lopez-Vivanco, G. Said: Randomized double blind (DB) placebo (Plcb) controlled phase III study
assessing the efficacy of xaliproden (X) in reducing the cumulative peripheral sensory neuropathy
(PSN) induced by the oxaliplatin (Ox) and 5-FU/LV combination (FOLFOX4) in first-line treatment
of patients (pts) with metastatic colorectal cancer (MCRC). Journal of Clinical Oncology, 2006 ASCO
Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 3507
34. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF,
Bast RC Jr; ASCO.: ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal
250 Gastro Update 2007
cancer. J Clin Oncol. 2006 Nov 20;24 (33):5313-27. Epub 2006 Oct 23.
35. Antoniou A, Lovegrove RE, Tilney HS, Heriot AG, John TG, Rees M, Tekkis PP, Welsh FK.: Meta-analysis of
clinical outcome after first and second liver resection for colorectal metastases. Surgery. 2007 Jan;141 (1):9-18.
36. Pawlik TM, Abdalla EK, Ellis LM, Vauthey JN, Curley SA.: Debunking dogma: surgery for four or more
colorectal liver metastases is justified. J Gastrointest Surg. 2006 Feb;10 (2):240-8.
37. Benoist S, Brouquet A, Penna C, Julie C, El Hajjam M, Chagnon S, Mitry E, Rougier P, Nordlinger B.:
Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol.
2006 Aug 20;24 (24):3939-45.
38. Aloia TA, Vauthey JN, Loyer EM, Ribero D, Pawlik TM, Wei SH, Curley SA, Zorzi D, Abdalla EK.:
Solitary colorectal liver metastasis: resection determines outcome. Arch Surg. 2006 May;141 (5):460-
6;discussion 466-7.
39. Minagawa M, Yamamoto J, Miwa S, Sakamoto Y, Kokudo N, Kosuge T, Miyagawa S, Makuuchi M.:
Selection criteria for simultaneous resection in patients with synchronous liver metastasis. Arch Surg.
2006 Oct;141 (10):1006-12; discussion 1013.
